Age-dependent myeloid dendritic cell responses mediate resistance to la crosse virus-induced neurological disease

Journal of Virology

Volumn 88, Issue 19, 2014, Pages 11070-11079

  Taylor, Katherine G ^a   Woods, Tyson A ^a   Winkler, Clayton W ^a   Carmody, Aaron B ^a   Peterson, Karin E ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD11B ANTIGEN; GLYCOPROTEIN P 15095; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; LIPOSOME; MAVS PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; UNC93B1 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AGE; ARTICLE; CALIFORNIA ENCEPHALITIS; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENDOSOME; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE RESPONSE; INFECTION RESISTANCE; INNATE IMMUNITY; LA CROSSE VIRUS; MOUSE; MYELOID DENDRITIC CELL; NEUROLOGIC DISEASE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UNITED STATES; VIRUS REPLICATION; ANIMAL; BONE MARROW CELL; CENTRAL NERVOUS SYSTEM; DENDRITIC CELL; DISEASE MODEL; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRADERMAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MORTALITY; NEWBORN; SURVIVAL; VIROLOGY;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; CENTRAL NERVOUS SYSTEM; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; ENCEPHALITIS, CALIFORNIA; GENE EXPRESSION; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; INTERFERON TYPE I; LA CROSSE VIRUS; MICE; MYELOID CELLS; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTORS; VIRUS REPLICATION;

EID: 84906987158     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01866-14     Document Type: Article

References (38)

1. Haddow AD, Jones CJ, Odoi A. 2009. Assessing risk in focal arboviral infections: are we missing the big or little picture? PLoS One 4:e6954. http://dx.doi.org/10.1371/journal.pone.0006954.
2. Haddow AD, Odoi A. 2009. The incidence risk, clustering, and clinical presentation of La Crosse virus infections in the eastern United States, 2003-2007. PLoS One 4:e6145. http://dx.doi.org/10.1371/journal.pone .0006145.
3. Prendergast AJ, Klenerman P, Goulder PJ. 2012. The impact of differential antiviral immunity in children and adults. Nat. Rev. Immunol. 12: 636-648. http://dx.doi.org/10.1038/nri3277.
4. Armstrong PM, Andreadis TG. 2006. A new genetic variant of La Crosse virus (bunyaviridae) isolated from New England. Am. J. Trop. Med. Hyg. 75:491-496.
5. Gerhardt RR, Gottfried KL, Apperson CS, Davis BS, Erwin PC, Smith AB, Panella NA, Powell EE, Nasci RS. 2001. First isolation of La Crosse virus from naturally infected Aedes albopictus. Emerg. Infect. Dis. 7:807-811. http://dx.doi.org/10.3201/eid0705.010506.
6. Haddow AD, Bixler D, Odoi A. 2011. The spatial epidemiology and clinical features of reported cases of La Crosse virus infection in West Virginia from 2003 to 2007. BMC Infect. Dis. 11:29. http://dx.doi.org/10 .1186/1471-2334-11-29.
7. Sotir MJ, Glaser LC, Fox PE, Doering M, Geske DA, Warshauer DM, Davis JP. 2007. Endemic human mosquito-borne disease in Wisconsin residents, 2002-2006. WMJ 106:185-190.
8. Janssen R, Gonzalez-Scarano F, Nathanson N. 1984. Mechanisms of bunyavirus virulence. Comparative pathogenesis of a virulent strain of La Crosse and an avirulent strain of Tahyna virus. Lab. Invest. 50:447-455.
9. Johnson RT. 1983. Pathogenesis of La Crosse virus in mice. Prog. Clin. Biol. Res. 123:139-144.
10. Pavlovic J, Schultz J, Hefti HP, Schuh T, Molling K. 2000. DNA vaccination against La Crosse virus. Intervirology 43:312-321. http://dx .doi.org/10.1159/000053999.
11. Pekosz A, Griot C, Stillmock K, Nathanson N, Gonzalez-Scarano F. 1995. Protection from La Crosse virus encephalitis with recombinant glycoproteins: role of neutralizing anti-G1 antibodies. J. Virol. 69:3475-3481.
12. Barchet W, Cella M, Colonna M. 2005. Plasmacytoid dendritic cells- virus experts of innate immunity. Semin. Immunol. 17:253-261. http://dx .doi.org/10.1016/j.smim.2005.05.008.
13. Ramos HJ, Gale M, Jr. 2011. RIG-I like receptors and their signaling crosstalk in the regulation of antiviral immunity. Curr. Opin. Virol. 1:167-176. http://dx.doi.org/10.1016/j.coviro.2011.04.004.
14. Sorgeloos F, Kreit M, Hermant P, Lardinois C, Michiels T. 2013. Antiviral type I and type III interferon responses in the central nervous system. Viruses 5:834-857. http://dx.doi.org/10.3390/v5030834.
15. Lazear HM, Lancaster A, Wilkins C, Suthar MS, Huang A, Vick SC, Clepper L, Thackray L, Brassil MM, Virgin HW, Nikolich-Zugich J, Moses AV, Gale M, Jr, Fruh K, Diamond MS. 2013. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog. 9:e1003118. http://dx .doi.org/10.1371/journal.ppat.1003118.
16. Daffis S, Suthar MS, Gale M, Jr., Diamond MS. 2009. Measure and countermeasure: type I IFN (IFN-alpha/beta) antiviral response against West Nile virus. J. Innate Immun. 1:435-445. http://dx.doi.org/10.1159 /000226248.
17. Lenschow DJ, Lai C, Frias-Staheli N, Giannakopoulos NV, Lutz A, Wolff T, Osiak A, Levine B, Schmidt RE, Garcia-Sastre A, Leib DA, Pekosz A, Knobeloch KP, Horak I, Virgin HW. 2007. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl. Acad. Sci. U. S. A. 104:1371-1376. http: //dx.doi.org/10.1073/pnas.0607038104.
18. Zhang Y, Burke CW, Ryman KD, Klimstra WB. 2007. Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. J. Virol. 81:11246 -11255. http://dx.doi.org/10.1128 /JVI.01282-07.
19. Ryman KD, Gardner CL, Meier KC, Biron CA, Johnston RE, Klimstra WB. 2007. Early restriction of alphavirus replication and dissemination contributes to age-dependent attenuation of systemic hyperinflammatory disease. J. Gen. Virol. 88:518-529. http://dx.doi.org/10.1099/vir.0.82359-0.
20. Marr N, Wang TI, Kam SH, Hu YS, Sharma AA, Lam A, Markowski J, Solimano A, Lavoie PM, Turvey SE. 2014. Attenuation of respiratory syncytial virus-induced and RIG-I-dependent type I IFN responses in human neonates and very young children. J. Immunol. 192:948-957. http: //dx.doi.org/10.4049/jimmunol.1302007.
21. Rudd PA, Wilson J, Gardner J, Larcher T, Babarit C, Le TT, Anraku I, Kumagai Y, Loo YM, Gale M, Jr., Akira S, Khromykh AA, Suhrbier A. 2012. Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock. J. Virol. 86:9888-9898. http://dx.doi .org/10.1128/JVI.00956-12.
22. Daffis S, Suthar MS, Szretter KJ, Gale M, Jr., Diamond MS. 2009. Induction of IFN-beta and the innate antiviral response in myeloid ells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. PLoS Pathog. 5:e1000607. http://dx.doi.org/10.1371/journal.ppat .1000607.
23. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9:143-150. http://dx.doi.org/10.1016/S1074-7613(00)80596-8.
24. Bennett RS, Cress CM, Ward JM, Firestone CY, Murphy BR, Whitehead SS. 2008. La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys. Virol. J. 5:25. http://dx.doi.org/10.1186/1743 -422X-5-25.
25. Bennett RS, Ton DR, Hanson CT, Murphy BR, Whitehead SS. 2007. Genome sequence analysis of La Crosse virus and in vitro and in vivo phenotypes. Virol. J. 4:41. http://dx.doi.org/10.1186/1743-422X-4-41.
26. Butchi NB, Woods T, Du M, Morgan TW, Peterson KE. 2011. TLR7 and TLR9 trigger distinct neuroinflammatory responses in the CNS. Am. J. Pathol. 179:783-794. http://dx.doi.org/10.1016/j.ajpath.2011.04.011.
27. Johnson KP, Johnson RT. 1968. California encephalitis. II. Studies of experimental infection in the mouse. J. Neuropathol. 27:390-400.
28. Dixit E, Kagan JC. 2013. Intracellular pathogen detection by RIG-I-like receptors. Adv. Immunol. 117:99-125. http://dx.doi.org/10.1016/B978-0 -12-410524-9.00004-9.
29. Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, Crozat K, Mudd S, Mann N, Sovath S, Goode J, Shamel L, Herskovits AA, Portnoy DA, Cooke M, Tarantino LM, Wiltshire T, Steinberg BE, Grinstein S, Beutler B. 2006. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat. Immunol. 7:156-164. http://dx.doi.org/10.1038/ni1297.
30. Mukherjee P, Woods TA, Moore RA, Peterson KE. 2013. Activation of the innate signaling molecule MAVS by bunyavirus infection upregulates the adaptor protein SARM1, leading to neuronal death. Immunity 38: 705-716. http://dx.doi.org/10.1016/j.immuni.2013.02.013.
31. Monkkonen J, van Rooijen N, Ylitalo P. 1991. Effects of clodronate and pamidronate on splenic and hepatic phagocytic cells of mice. Pharmacol. Toxicol. 68:284-286. http://dx.doi.org/10.1111/j.1600-0773.1991.tb01240.x.
32. Wang C, Zhuang Y, Zhang Y, Luo Z, Gao N, Li P, Pan H, Cai L, Ma Y. 2012. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells. Vaccine 30:4790-4799. http://dx.doi.org/10.1016/j.vaccine.2012.05.027.
33. Verbruggen P, Ruf M, Blakqori G, Overby AK, Heidemann M, Eick D, Weber F. 2011. Interferon antagonist NSs of La Crosse virus triggers a DNA damage response-like degradation of transcribing RNA polymerase II. J. Biol. Chem. 286:3681-3692. http://dx.doi.org/10.1074/jbc.M110 .154799.
34. Corbett NP, Blimkie D, Ho KC, Cai B, Sutherland DP, Kallos A, Crabtree J, Rein-Weston A, Lavoie PM, Turvey SE, Hawkins NR, Self SG, Wilson CB, Hajjar AM, Fortuno ESIII, Kollmann TR. 2010. Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One 5:e15041. http://dx.doi.org/10.1371/journal .pone.0015041.
35. Dakic A, Shao QX, D'Amico A, O'Keeffe M, Chen WF, Shortman K, Wu L. 2004. Development of the dendritic cell system during mouse ontogeny. J. Immunol. 172:1018-1027. http://dx.doi.org/10.4049/jimmunol.172.2.1018.
36. Vollstedt S, Franchini M, Hefti HP, Odermatt B, O'Keeffe M, Alber G, Glanzmann B, Riesen M, Ackermann M, Suter M. 2003. Flt3 ligandtreated neonatal mice have increased innate immunity against intracellular pathogens and efficiently control virus infections. J. Exp. Med. 197: 575-584. http://dx.doi.org/10.1084/jem.20021900.
37. Willems F, Vollstedt S, Suter M. 2009. Phenotype and function of neonatal DC. Eur. J. Immunol. 39:26 -35. http://dx.doi.org/10.1002/eji .200838391.
38. Blakqori G, Delhaye S, Habjan M, Blair CD, Sanchez-Vargas I, Olson KE, Attarzadeh-Yazdi G, Fragkoudis R, Kohl A, Kalinke U, Weiss S, Michiels T, Staeheli P, Weber F. 2007. La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts. J. Virol. 81:4991-4999. http://dx.doi.org/10.1128/JVI.01933-06.